- $265.90m
- $530.98m
- CA$297.15m
- 32
- 64
- 12
- 28
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.75 | ||
| Price to Tang. Book | 1.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.05% | ||
| Return on Equity | -93.04% | ||
| Operating Margin | -78.16% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 398.77 | 546.65 | 510.32 | 333.25 | 297.15 | 274.48 | 294.37 | 5.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.
Directors
- Judy Schmeling NEC (61)
- David Klein CEO (57)
- Judy Hong CFO (50)
- Julious Grant OTH (53)
- Tara Rozalowsky OTH
- Phillip Shaer SEC (47)
- Garth Hankinson DRC (53)
- Robert Hanson IND (58)
- David Lazzarato IND (65)
- James Sabia IND (60)
- Theresa Yanofsky IND (64)
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- August 5th, 2009
- Public Since
- June 4th, 2010
- No. of Employees
- 1,029
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 108,942,861
- Address
- 1 Hershey Dr, SMITHS FALLS, K7A 0A8
- Web
- https://www.canopygrowth.com/
- Phone
- +1 6135999600
- Auditors
- PKF O'Connor Davies
Latest News for CGC
Upcoming Events for CGC
Q3 2025 Canopy Growth Corp Earnings Release
Q4 2025 Canopy Growth Corp Earnings Release
Similar to CGC
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:47 UTC, shares in Canopy Growth are trading at $2.45. This share price information is delayed by 15 minutes.
Shares in Canopy Growth last closed at $2.45 and the price had moved by -44.57% over the past 365 days. In terms of relative price strength the Canopy Growth share price has underperformed the S&P500 Index by -54.49% over the past year.
The overall consensus recommendation for Canopy Growth is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCanopy Growth does not currently pay a dividend.
Canopy Growth does not currently pay a dividend.
Canopy Growth does not currently pay a dividend.
To buy shares in Canopy Growth you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.45, shares in Canopy Growth had a market capitalisation of $265.90m.
Here are the trading details for Canopy Growth:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CGC
Based on an overall assessment of its quality, value and momentum Canopy Growth is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Canopy Growth is $4.74. That is 93.58% above the last closing price of $2.45.
Analysts covering Canopy Growth currently have a consensus Earnings Per Share (EPS) forecast of -CA$3.44 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Canopy Growth. Over the past six months, its share price has underperformed the S&P500 Index by -63.57%.
As of the last closing price of $2.45, shares in Canopy Growth were trading -60.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Canopy Growth PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Canopy Growth's management team is headed by:
- Judy Schmeling - NEC
- David Klein - CEO
- Judy Hong - CFO
- Julious Grant - OTH
- Tara Rozalowsky - OTH
- Phillip Shaer - SEC
- Garth Hankinson - DRC
- Robert Hanson - IND
- David Lazzarato - IND
- James Sabia - IND
- Theresa Yanofsky - IND